-+ 0.00%
-+ 0.00%
-+ 0.00%
AstraZeneca's Imfinzi Combo Therapy Wins US FDA Nod for Bladder Cancer Treatment
Share
Listen to the news
01:26 AM EST, 11/15/2026 (MT Newswires) -- The US Food and Drug Administration approved AstraZeneca's (AZN.L, AZN.ST) Imfinzi in combination with enfortumab vedotin as neoadjuvant therapy for patients with muscle-invasive bladder cancer who are unsuitable for, or have declined, cisplatin-based chemotherapy. The US clearance was supported by the drugmaker's Volga phase 3 study, where it showed a 49% decrease in disease progression risk, recurrence, not undergoing surgery, or death, compared with radical cystectomy with or without adjuvant treatment, according to a Nov. 13 release. The study also demonstrated that the Imfinzi combo reduced the risk of death by 42%, with its safety and tolerability consistent with its known safety profile. AstraZeneca added that the combo treatment is under evaluation in the European Union, Japan, and other countries.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending